Other substances

Prasugrel

A thienopyridine platelet aggregation inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
1
 Clinical trials

General information

Prasugrel on PubChem

Marketed as

EFFIENT; PRASITA; PRASUGREL

 

Structure image - Prasugrel

CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4

Supporting references

Link Tested on Impact factor Notes Publication date
Superiority of cilostazol among antiplatelet FDA‐approved drugs against COVID 19 Mpro and spike protein: Drug repurposing approach
Spike protein 3CLpro Small molecule In silico Screening 		in silico 1.90

Predicted to inhibit the SARS-CoV-2 spike protein.

 Sep/27/2020

AI-suggested references

Link Publication date
Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective
Sep/12/2021
Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 Mpro and spike protein: Drug repurposing approach
Jan/22/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04445623 Prasugrel in Severe COVID-19 Pneumonia Not yet recruiting Phase 3 Jul/01/2020 Jan/01/2021
  • Alternative id - MGI-COVID-19-prasugrel
  • Interventions - Drug: Prasugrel Hydrochloride 10 MG Oral Tablet|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
  • Enrollment - 128
  • Age - 18 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - P/F ratio at day 7|Daily P/F ratio|Daily need for oxygen supply|Need for ICU|Death|MOF|Discharge|Clinical progression of the disease SOFA score|Clinical progression of the disease APACHE II|Venous thrombosis/ pulmonary embolism/thrombosis|Need for CT imaging|Daily Temperature|Daily blood pressure|Daily total blood count Hemoglobin|Daily total blood count Red Blood Cells|Daily total blood count Leukocytes|Daily total blood count Platelets|Daily indices of organ damage Liver|Indices of inflammation C-reactive protein|Indices of haemostasis PT|Daily progression at imaging (chest-X-ray)|Major bleeding|Total bleeding|Unexpected clinical or laboratory findings|Indices of inflammation D-dimer|Indices of inflammation Fibrinogen|Indices of inflammation IL-6|Indices of inflammation IL-1|Daily indices of organ damage kidney|Daily indices of organ damage heart|Haemostasis aPTT|Haemostasis VASP PRI|Haemostasis platelet-leukocytes aggregates
Export (.csv)